Viking Therapeutics Quarterly Cash Flow Statement
NASDAQ: VKTXHealthcareBiotechnologyUSD
28.51+0.78 (+2.81%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viking Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Viking Therapeutics generated -$125.2 million of operating cash flow. That left free cash flow of -$125.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Viking Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -128.02M | -158.32M | -157.66M | -90.79M | -65.56M | -45.63M | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M | -22.53M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 11.13M | 10.34M | 8.59M | 7.34M | 13.55M | 11.35M | 5.67M | 8.98M | 7.08M | 7.98M | 4.08M | 4.48M |
| Change in Working Capital | -7.57M | 34.42M | 65.18M | -10.72M | 7.34M | -17.40M | 3.23M | -2.28M | -7.77M | 15.38M | 5.67M | 1.30M |
| Operating Cash Flow | -125.17M | -113.98M | -85.29M | -94.00M | -47.06M | -52.33M | -31.18M | -21.96M | -28.51M | -6.13M | -17.64M | -19.66M |
| Investing Cash Flow | 109.43M | 54.19M | 75.61M | 160.03M | 42.51M | 63.24M | 6.58M | 25.90M | -126.06M | -459.79M | 35.73M | -12.53M |
| Financing Cash Flow | 23.59M | 12.08M | 75.10M | 480.00K | 507.00K | 349.00K | 1.00M | 2.52M | 2.90M | 606.04M | 188.00K | -74.00K |
| Net Change in Cash | 7.84M | -47.71M | 65.42M | 66.50M | -4.05M | 11.26M | -23.60M | 6.46M | -151.67M | 140.11M | 18.28M | -32.27M |
| Free Cash Flow | -125.17M | -113.98M | -85.29M | -94.00M | -47.06M | -52.33M | -31.18M | -21.96M | -28.51M | -6.13M | -17.64M | -19.66M |
This table shows 12 quarterly periods of Viking Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 9 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow VKTX's reporting calendar. What is a cash flow statement?